AG
TGTX icon

Advisor Group’s TG Therapeutics TGTX Stock Holding History

Advisor Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$157K Buy
14,150
+5,400
+62% +$41.1K ﹤0.01% 2586
2019
Q3 		$49K Buy
8,750
+900
+11% +$6.28K ﹤0.01% 3410
2019
Q2 		$68K Hold
7,850
– – ﹤0.01% 3153
2019
Q1 		$63K Buy
7,850
+1,500
+24% +$8.11K ﹤0.01% 3226
2018
Q4 		$26K Buy
6,350
+1,485
+31% +$7.38K ﹤0.01% 3638
2018
Q3 		$27K Buy
4,865
+500
+11% +$5.71K ﹤0.01% 3700
2018
Q2 		$57K Buy
4,365
+600
+16% +$8.25K ﹤0.01% 2980
2018
Q1 		$54K Sell
3,765
-850
-18% -$10.9K ﹤0.01% 3004
2017
Q4 		$38K Buy
4,615
+3,700
+404% +$32.3K ﹤0.01% 3282
2017
Q3 		$11K Hold
915
– – ﹤0.01% 3922
2017
Q2 		$9K Sell
915
-300
-25% -$3.36K ﹤0.01% 3995
2017
Q1 		$14K Buy
1,215
+400
+49% +$2.87K ﹤0.01% 3599
2016
Q4 		$4K Buy
815
+200
+33% +$1.17K ﹤0.01% 4044
2016
Q3 		$5K Hold
615
– – ﹤0.01% 3905
2016
Q2 		$3K Buy
+615
New +$5K ﹤0.01% 4004

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advisor Group's TGTX Position: Q4 2019 in Review

Advisor Group increased its TG Therapeutics (TGTX) stake by 62% in Q4 2019, buying an estimated $41.1K and bringing the position to 14,150 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #2586.

Advisor Group first reported a position in TGTX in Q2 2016 and has held it in 15 quarters since. 135 funds tracked by Wall St. Rank hold TGTX as of Q4 2019.

  • Advisor Group held 14,150 shares of TG Therapeutics worth $157K as of Q4 2019.
  • Advisor Group bought 5,400 TG Therapeutics shares in Q4 2019, an estimated $41.1K.
  • TG Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2586 holding.
  • Advisor Group first reported a position in TG Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • 135 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.